Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer
一项针对晚期非小细胞肺癌患者的I期研究,评估腺苷2A受体拮抗剂Taminadenant(PBF509/NIR178)联合或不联合Spartalizumab(PDR001)的疗效。
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-2742
Chiappori, Alberto A; Creelan, Ben; Tanvetyanon, Tawee; Gray, Jhanelle E; Haura, Eric B; Thapa, Ram; Barlow, Margaret L; Chen, Zhihua; Chen, Dung Tsa; Beg, Amer A; Boyle, Theresa A; Castro, Julio; Morgan, Liza; Morris, Erick; Aregay, Mehreteab; Hurtado, Felipe K; Manenti, Luigi; Antonia, Scott